Comparing Type 2 Diabetes Drug Therapies
A new evidence review compares the weekly glucagon-like peptide-1 receptor agonists (GLP-1RAs) for the treatment of type 2 diabetes. Three of the drugs are marketed in the United States, including dulaglutide (Trulicity), once weekly exenatide (Bydureon), and albiglutide (Tanzeum). Other drugs in the review included semaglutide, which is in Phase III trials, and taspoglutide, which is no longer in development. Each drug reduced A1c levels, with dulaglutide and taspoglutide resulting in the greatest difference (-0.4%; 95% confidence interval, -0.7% to -0.2%). Semaglutide and taspoglutide also resulted in the largest reduction in body weight, although once-weekly exenatide also reduced weight but to a lesser degree. Each drug had minimal to no effect on blood pressure, blood lipids, or C-reactive protein levels (Ann Int Med published online Dec. 8, 2015; doi:10.7326/M15-1432). Taspoglutide had a significant risk for nausea, a side effect that derailed the drug’s development. Several once-a-day GLP-1RAs are also on the market, including liraglutide (Victoza) and exenatide (Byetta).
A new evidence review compares the weekly glucagon-like peptide-1 receptor agonists for the treatment of type 2 diabetes.
Subscribe Now for Access
You have reached your article limit for the month. We hope you found our articles both enjoyable and insightful. For information on new subscriptions, product trials, alternative billing arrangements or group and site discounts please call 800-688-2421. We look forward to having you as a long-term member of the Relias Media community.